Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Post by deninsaskon Jan 18, 2008 12:27pm
160 Views
Post# 14225150

The Gin-102 MAD TT-223 Study.......polak

The Gin-102 MAD TT-223 Study.......polak Sorry Polak its the 201 Phasell Trial that has similar timelines to TT-223+EGF.....except that it will be a 3 month Repeat Dose. The Gin-102 MAD TT-223 Study was to start in Dec. The Gin-101 SAD TT-223 Study started in Sept. and is COMPLETE. Both designed to also to find the DLP for TT-223. Cheers.
Bullboard Posts